News | January 23, 2026
EMA hits record high in vet medicine nods for second year running
EMA recommended 30 veterinary medicines for marketing authorisation in 2025
EMA recommended 30 veterinary medicines for marketing authorisation in 2025
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The study evaluated patients with stage III/IV melanoma after complete tumor resection
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
The collaboration will focus on enhancing surgeon capabilities, developing structured training pathways, and promoting the adoption of robotic-assisted surgery in both routine and complex procedures
Improvements were also seen in complete response rates, duration of response, and time to next treatment
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
Subscribe To Our Newsletter & Stay Updated
